<p>STAAR Surgical（納斯達克股票代碼：STAA - 獲取免費報告）在週六發佈給投資者的研究報告中，被華爾街 Zen 的股票分析師從 “持有” 評級上調至 “買入” 評級。</p>
<p>獲取 <strong>STAAR Surgical</strong> 的提醒：</p>
<ul>
<li>4 只內部人士顯著買入的股票</li>
</ul>
<p>其他分析師最近也發佈了關於該股票的研究報告。Stifel Nicolaus 將 STAAR Surgical 的目標價從 18.00 美元上調至 31.00 美元，並在週四的報告中給予該股票 “持有” 評級。Canaccord Genuity Group 將 STAAR Surgical 的目標價從 27.00 美元上調至 32.00 美元，並在週四的報告中給予該股票 “買入” 評級。摩根士丹利在 1 月 16 日的報告中開始覆蓋 STAAR Surgical 的股票，給予 “減持” 評級和 13.00 美元的目標價。Piper Sandler 將 STAAR Surgical 的目標價從 16.00 美元上調至 33.00 美元，並在週四的報告中給予該股票 “中性” 評級。最後，Wedbush 將 STAAR Surgical 的評級從 “中性” 上調至 “跑贏大盤”，並在週四的報告中將該股票的目標價從 26.00 美元上調至 40.00 美元。三位分析師給予該股票 “買入” 評級，六位分析師給予 “持有” 評級，二位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “持有”，共識目標價為 27.81 美元。</p>
<p><strong>查看我們關於 STAAR Surgical 的最新研究報告</strong></p>
<h2>STAAR Surgical 股票上漲 0.2%</h2>
<ul>
<li>隨着 2024 年美國前景改善，Star Surgical 表現亮眼</li>
</ul>
<p>週五，納斯達克 STAA 的股票開盤價為 32.07 美元。該公司的市值為 16 億美元，市盈率為-74.58，貝塔係數為 1.20。STAAR Surgical 的 52 周最低價為 15.59 美元，52 周最高價為 35.87 美元。該公司的 50 日移動平均價格為 22.74 美元，200 日移動平均價格為 22.65 美元。公司的速動比率為 3.74，流動比率為 5.12，債務與股本比率為 0.09。</p>
<p>STAAR Surgical（納斯達克股票代碼：STAA - 獲取免費報告）最後一次發佈季度財報是在 5 月 13 日，醫療器械供應商報告該季度每股收益為 0.10 美元，超出分析師共識預期的 0.05 美元。該公司該季度的收入為 9352 萬美元，而共識預期為 7872 萬美元。STAAR Surgical 的淨利潤率為-7.24%，股本回報率為 3.31%。該公司的收入同比增長 119.6%。在去年同期，該公司每股收益為-1.10 美元。股票研究分析師預計 STAAR Surgical 在當前財年將發佈-0.03 美元的每股收益。</p>
<h2>STAAR Surgical 的內部交易</h2>
<p>在其他 STAAR Surgical 的新聞中，董事 Broadwood Partners, L.P.在 3 月 13 日的交易中購買了 316,017 股該公司的股票。該股票的平均購買價格為每股 18.61 美元，總交易額為 5,881,076.37 美元。交易完成後，該董事在公司持有 16,123,842 股，估值約為 300,064,699.62 美元。此次交易使其持股增加了 2.00%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。在過去的九十天裏，內部人士共購買了 670,213 股公司股票，價值為 12,266,249 美元。內部人士持有公司 39.90% 的股份。</p>
<h2>對 STAAR Surgical 的對沖基金看法</h2>
<p>一些對沖基金和其他機構投資者最近增加或減少了在 STAA 的持股。凱通國際資產管理有限公司在第三季度將其在 STAAR Surgical 的持股增加了 2,605.1%。凱通國際資產管理有限公司現在持有 1,055 股醫療器械供應商的股票，價值 28,000 美元，此前在上個季度又購買了 1,016 股。Ascentis Independent Advisors 在第一季度獲得了 STAAR Surgical 的新頭寸，估值約為 77,000 美元。Tower Research Capital LLC TRC 在第二季度將其在 STAAR Surgical 的持股增加了 375.0%。Tower Research Capital LLC TRC 現在持有 5,919 股醫療器械供應商的股票，價值 99,000 美元，此前在上個季度又購買了 4,673 股。拉塞爾投資集團有限公司在第三季度將其在 STAAR Surgical 的持股增加了 9,928.9%。拉塞爾投資集團有限公司現在持有 4,513 股醫療器械供應商的股票，價值 121,000 美元，此前在上個季度又購買了 4,468 股。最後，Wolverine Asset Management LLC 在第三季度獲得了 STAAR Surgical 的新頭寸，估值約為 199,000 美元。機構投資者和對沖基金持有公司 96.70% 的股份。</p>
<h2>更多 STAAR Surgical 新聞</h2>
<p>以下是本週影響 STAAR Surgical 的主要新聞故事：</p>
<ul>
<li>積極情緒：STAAR Surgical 超過了第一季度的盈利和收入預期，業務實現盈利，並顯示出強勁的同比改善。Staar Surgical (STAA) 超過第一季度盈利和收入預期</li>
<li>積極情緒：Wedbush 將 STAA 升級為 <strong>跑贏大盤</strong>，並將其目標價提高至 40 美元，理由是與中國復甦相關的前景改善。STAAR Surgical 被 Wedbush 升級</li>
<li>積極情緒：瑞穗證券對該股票的看法也變得更加積極，目標價上調，反映出更好的盈利動能和前景預期。瑞穗證券對 STAAR Surgical 股票價格發佈積極預測</li>
<li>積極情緒：關於財報電話會議的評論強調了中國市場的強勁、成本控制和庫存穩定作為業務轉機的驅動因素。Staar Surgical 在中國市場強勁的背景下發出明顯的轉機信號</li>
<li>中性情緒：富國銀行將其目標價提高至 25 美元，但維持 <strong>持平</strong> 評級，儘管近期反彈，仍顯示出一些謹慎。STAAR Surgical 的目標價被富國銀行上調</li>
<li>消極情緒：一些分析師仍然認為 STAAR Surgical 2026 年的前景有限，新的風險披露增加了對未來表現和估值的不確定性。Staar Surgical 面臨加劇的不確定性</li>
</ul>
<h2>關於 STAAR Surgical</h2>
<p>(獲取免費報告)</p>
<p>STAAR Surgical Company 及其子公司設計、開發、製造、營銷和銷售可植入眼內鏡片及其伴隨的輸送系統，以將鏡片植入眼內。該公司提供可植入的 Collamer 鏡片產品系列 (ICLs)，用於治療視覺障礙，如近視、遠視、散光和老花眼。它將產品銷售給醫療保健提供者，包括眼科外科醫生、視力和外科中心、醫院、政府機構和分銷商，產品主要由眼科醫生使用。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 STAAR Surgical</li>
<li>Viking 股價創歷史新高——基本面信號顯示未來還有更多</li>
<li>Datavalut 獲得關注：現在賣出的五個理由</li>
<li>TMC 股票：為什麼這家未盈利的礦業公司值得關注</li>
<li>電網正在衰退——是時候購買其替代品了嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RBQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RBQQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 STAAR Surgical 嗎？</h2>
<p>在考慮 STAAR Surgical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前購買的股票……而 STAAR Surgical 並不在名單上。</p>
<p>雖然 STAAR Surgical 目前在分析師中獲得持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

達視光學

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

<p>華爾街禪將 STAAR Surgical（納斯達克代碼：STAA）的評級從 “持有” 上調至 “買入”。其他分析師也提高了他們的目標價，Stifel Nicolaus 將其從 18 美元上調至 31 美元，Canaccord Genuity 則從 27 美元上調至 32 美元。該股票開盤價為 32.07 美元，市值為 16 億美元。最近的財報顯示，收入同比增長 119.6%，每股收益為 0.10 美元，超出預期</p>

<p>STAAR Surgical (NASDAQ:STAA - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note issued to investors on Saturday.</p>
<div class="lb-trans"><p>STAAR Surgical（納斯達克股票代碼：STAA - 獲取免費報告）在週六發佈給投資者的研究報告中，被華爾街 Zen 的股票分析師從 “持有” 評級上調至 “買入” 評級。</p>
</div><p>Get <strong>STAAR Surgical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>STAAR Surgical</strong> 的提醒：</p>
</div><ul>
<li>Top 4 Stocks With Notable Insider Buying</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只內部人士顯著買入的股票</li>
</ul>
</div><p>Other analysts also recently issued research reports about the stock. Stifel Nicolaus boosted their price objective on shares of STAAR Surgical from $18.00 to $31.00 and gave the stock a &#34;hold&#34; rating in a report on Thursday. Canaccord Genuity Group boosted their price objective on shares of STAAR Surgical from $27.00 to $32.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday. Morgan Stanley started coverage on shares of STAAR Surgical in a report on Friday, January 16th. They set an &#34;underweight&#34; rating and a $13.00 price objective on the stock. Piper Sandler boosted their price objective on shares of STAAR Surgical from $16.00 to $33.00 and gave the stock a &#34;neutral&#34; rating in a report on Thursday. Finally, Wedbush raised shares of STAAR Surgical from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and boosted their price objective for the stock from $26.00 to $40.00 in a report on Thursday. Three analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of &#34;Hold&#34; and a consensus target price of $27.81.</p>
<div class="lb-trans"><p>其他分析師最近也發佈了關於該股票的研究報告。Stifel Nicolaus 將 STAAR Surgical 的目標價從 18.00 美元上調至 31.00 美元，並在週四的報告中給予該股票 “持有” 評級。Canaccord Genuity Group 將 STAAR Surgical 的目標價從 27.00 美元上調至 32.00 美元，並在週四的報告中給予該股票 “買入” 評級。摩根士丹利在 1 月 16 日的報告中開始覆蓋 STAAR Surgical 的股票，給予 “減持” 評級和 13.00 美元的目標價。Piper Sandler 將 STAAR Surgical 的目標價從 16.00 美元上調至 33.00 美元，並在週四的報告中給予該股票 “中性” 評級。最後，Wedbush 將 STAAR Surgical 的評級從 “中性” 上調至 “跑贏大盤”，並在週四的報告中將該股票的目標價從 26.00 美元上調至 40.00 美元。三位分析師給予該股票 “買入” 評級，六位分析師給予 “持有” 評級，二位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “持有”，共識目標價為 27.81 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on STAAR Surgical</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 STAAR Surgical 的最新研究報告</strong></p>
</div><h2>STAAR Surgical Stock Up 0.2%</h2>
<div class="lb-trans"><h2>STAAR Surgical 股票上漲 0.2%</h2>
</div><ul>
<li>Star Surgical Shines as U.S. Outlook Improves for 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>隨着 2024 年美國前景改善，Star Surgical 表現亮眼</li>
</ul>
</div><p>Shares of NASDAQ STAA opened at $32.07 on Friday. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -74.58 and a beta of 1.20. STAAR Surgical has a 52 week low of $15.59 and a 52 week high of $35.87. The firm has a 50-day moving average price of $22.74 and a 200 day moving average price of $22.65. The company has a quick ratio of 3.74, a current ratio of 5.12 and a debt-to-equity ratio of 0.09.</p>
<div class="lb-trans"><p>週五，納斯達克 STAA 的股票開盤價為 32.07 美元。該公司的市值為 16 億美元，市盈率為-74.58，貝塔係數為 1.20。STAAR Surgical 的 52 周最低價為 15.59 美元，52 周最高價為 35.87 美元。該公司的 50 日移動平均價格為 22.74 美元，200 日移動平均價格為 22.65 美元。公司的速動比率為 3.74，流動比率為 5.12，債務與股本比率為 0.09。</p>
</div><p>STAAR Surgical (NASDAQ:STAA - Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The medical instruments supplier reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $0.05. The firm had revenue of $93.52 million for the quarter, compared to the consensus estimate of $78.72 million. STAAR Surgical had a negative net margin of 7.24% and a positive return on equity of 3.31%. The firm's revenue was up 119.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.10) earnings per share. Equities research analysts anticipate that STAAR Surgical will post -0.03 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>STAAR Surgical（納斯達克股票代碼：STAA - 獲取免費報告）最後一次發佈季度財報是在 5 月 13 日，醫療器械供應商報告該季度每股收益為 0.10 美元，超出分析師共識預期的 0.05 美元。該公司該季度的收入為 9352 萬美元，而共識預期為 7872 萬美元。STAAR Surgical 的淨利潤率為-7.24%，股本回報率為 3.31%。該公司的收入同比增長 119.6%。在去年同期，該公司每股收益為-1.10 美元。股票研究分析師預計 STAAR Surgical 在當前財年將發佈-0.03 美元的每股收益。</p>
</div><h2>Insider Transactions at STAAR Surgical</h2>
<div class="lb-trans"><h2>STAAR Surgical 的內部交易</h2>
</div><p>In other STAAR Surgical news, Director Broadwood Partners, L.P. bought 316,017 shares of the business's stock in a transaction on Friday, March 13th. The stock was bought at an average price of $18.61 per share, for a total transaction of $5,881,076.37. Following the completion of the transaction, the director owned 16,123,842 shares in the company, valued at approximately $300,064,699.62. The trade was a 2.00% increase in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 670,213 shares of company stock worth $12,266,249 in the last ninety days. Insiders own 39.90% of the company's stock.</p>
<div class="lb-trans"><p>在其他 STAAR Surgical 的新聞中，董事 Broadwood Partners, L.P.在 3 月 13 日的交易中購買了 316,017 股該公司的股票。該股票的平均購買價格為每股 18.61 美元，總交易額為 5,881,076.37 美元。交易完成後，該董事在公司持有 16,123,842 股，估值約為 300,064,699.62 美元。此次交易使其持股增加了 2.00%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。在過去的九十天裏，內部人士共購買了 670,213 股公司股票，價值為 12,266,249 美元。內部人士持有公司 39.90% 的股份。</p>
</div><h2>Hedge Funds Weigh In On STAAR Surgical</h2>
<div class="lb-trans"><h2>對 STAAR Surgical 的對沖基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STAA. Caitong International Asset Management Co. Ltd raised its position in STAAR Surgical by 2,605.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 1,016 shares during the last quarter. Ascentis Independent Advisors acquired a new position in shares of STAAR Surgical in the first quarter valued at approximately $77,000. Tower Research Capital LLC TRC raised its position in shares of STAAR Surgical by 375.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier's stock valued at $99,000 after buying an additional 4,673 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of STAAR Surgical by 9,928.9% in the third quarter. Russell Investments Group Ltd. now owns 4,513 shares of the medical instruments supplier's stock valued at $121,000 after buying an additional 4,468 shares during the last quarter. Finally, Wolverine Asset Management LLC acquired a new position in shares of STAAR Surgical in the third quarter valued at approximately $199,000. Institutional investors and hedge funds own 96.70% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近增加或減少了在 STAA 的持股。凱通國際資產管理有限公司在第三季度將其在 STAAR Surgical 的持股增加了 2,605.1%。凱通國際資產管理有限公司現在持有 1,055 股醫療器械供應商的股票，價值 28,000 美元，此前在上個季度又購買了 1,016 股。Ascentis Independent Advisors 在第一季度獲得了 STAAR Surgical 的新頭寸，估值約為 77,000 美元。Tower Research Capital LLC TRC 在第二季度將其在 STAAR Surgical 的持股增加了 375.0%。Tower Research Capital LLC TRC 現在持有 5,919 股醫療器械供應商的股票，價值 99,000 美元，此前在上個季度又購買了 4,673 股。拉塞爾投資集團有限公司在第三季度將其在 STAAR Surgical 的持股增加了 9,928.9%。拉塞爾投資集團有限公司現在持有 4,513 股醫療器械供應商的股票，價值 121,000 美元，此前在上個季度又購買了 4,468 股。最後，Wolverine Asset Management LLC 在第三季度獲得了 STAAR Surgical 的新頭寸，估值約為 199,000 美元。機構投資者和對沖基金持有公司 96.70% 的股份。</p>
</div><h2>More STAAR Surgical News</h2>
<div class="lb-trans"><h2>更多 STAAR Surgical 新聞</h2>
</div><p>Here are the key news stories impacting STAAR Surgical this week:</p>
<div class="lb-trans"><p>以下是本週影響 STAAR Surgical 的主要新聞故事：</p>
</div><ul>
<li>Positive Sentiment: STAAR Surgical beat Q1 earnings and revenue expectations, with the business swinging to a profit and showing strong year-over-year improvement. Staar Surgical (STAA) Tops Q1 Earnings and Revenue Estimates</li>
<li>Positive Sentiment: Wedbush upgraded STAA to <strong>Outperform</strong> and lifted its price target to $40, citing improving prospects tied to a China recovery. STAAR Surgical was upgraded by Wedbush</li>
<li>Positive Sentiment: Mizuho also turned more constructive on the stock with a higher price target, reflecting better earnings momentum and outlook expectations. Mizuho Issues Positive Forecast for STAAR Surgical Stock Price</li>
<li>Positive Sentiment: Commentary around the earnings call highlighted China strength, cost discipline, and stabilizing inventory as drivers of the turnaround. Staar Surgical Signals Sharp Turnaround Amid China Strength</li>
<li>Neutral Sentiment: Wells Fargo raised its price target to $25 but kept an <strong>Equal Weight</strong> rating, signaling some caution despite the recent rally. STAAR Surgical had its price target raised by Wells Fargo</li>
<li>Negative Sentiment: Some analysts still see limited visibility into STAAR Surgical’s 2026 outlook, and a new risk disclosure added to uncertainty around future performance and valuation. Staar Surgical Faces Heightened Uncertainty</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：STAAR Surgical 超過了第一季度的盈利和收入預期，業務實現盈利，並顯示出強勁的同比改善。Staar Surgical (STAA) 超過第一季度盈利和收入預期</li>
<li>積極情緒：Wedbush 將 STAA 升級為 <strong>跑贏大盤</strong>，並將其目標價提高至 40 美元，理由是與中國復甦相關的前景改善。STAAR Surgical 被 Wedbush 升級</li>
<li>積極情緒：瑞穗證券對該股票的看法也變得更加積極，目標價上調，反映出更好的盈利動能和前景預期。瑞穗證券對 STAAR Surgical 股票價格發佈積極預測</li>
<li>積極情緒：關於財報電話會議的評論強調了中國市場的強勁、成本控制和庫存穩定作為業務轉機的驅動因素。Staar Surgical 在中國市場強勁的背景下發出明顯的轉機信號</li>
<li>中性情緒：富國銀行將其目標價提高至 25 美元，但維持 <strong>持平</strong> 評級，儘管近期反彈，仍顯示出一些謹慎。STAAR Surgical 的目標價被富國銀行上調</li>
<li>消極情緒：一些分析師仍然認為 STAAR Surgical 2026 年的前景有限，新的風險披露增加了對未來表現和估值的不確定性。Staar Surgical 面臨加劇的不確定性</li>
</ul>
</div><h2>About STAAR Surgical</h2>
<div class="lb-trans"><h2>關於 STAAR Surgical</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.</p>
<div class="lb-trans"><p>STAAR Surgical Company 及其子公司設計、開發、製造、營銷和銷售可植入眼內鏡片及其伴隨的輸送系統，以將鏡片植入眼內。該公司提供可植入的 Collamer 鏡片產品系列 (ICLs)，用於治療視覺障礙，如近視、遠視、散光和老花眼。它將產品銷售給醫療保健提供者，包括眼科外科醫生、視力和外科中心、醫院、政府機構和分銷商，產品主要由眼科醫生使用。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than STAAR Surgical</li>
<li>Viking Sails to All-Time Highs—Fundamentals Signal More to Come</li>
<li>Datavalut Gains Traction: 5 Reasons to Sell Now</li>
<li>TMC Stock: Why This Pre-Revenue Miner Is Worth Watching</li>
<li>The Power Grid Is Dying—Is It Time to Buy Its Replacement?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 STAAR Surgical</li>
<li>Viking 股價創歷史新高——基本面信號顯示未來還有更多</li>
<li>Datavalut 獲得關注：現在賣出的五個理由</li>
<li>TMC 股票：為什麼這家未盈利的礦業公司值得關注</li>
<li>電網正在衰退——是時候購買其替代品了嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RBQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=STAA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in STAAR Surgical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 STAAR Surgical 嗎？</h2>
</div><p>Before you consider STAAR Surgical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 STAAR Surgical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前購買的股票……而 STAAR Surgical 並不在名單上。</p>
</div><p>While STAAR Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 STAAR Surgical 目前在分析師中獲得持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

STAAR Surgical (NASDAQ:STAA) Upgraded at Wall Street Zen

Market Beat

摩根士丹利

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

達視光學（NASDAQ:STAA）在 Wall Street Zen 獲得評級上調